Canopy Growth logged a wider loss in its fiscal second quarter, due to fair-value charges on its U.S. assets, overshadowing its international sales, which drove a surge in revenue.
For the three months ended Sept. 30, the cannabis company on Friday posted a widened net loss of 40.7 million Canadian dollars ($29 million), or C$0.10 a share, compared with a loss of C$5 million, or C$0.02 a share, in the comparable quarter a year ago.
The decline was largely due to C$35.8 million in fair value charges on the company's Canopy USA business and the assets related to it.
According to FactSet, analysts were expecting a loss of C$0.04 a share.
Consolidated revenue rose by 22% to C$81.4 million, but it was well below analyst forecasts of a greater rise to C$90.1 million.
Cannabis revenue rose 30% to C$66.2 million, thanks to gains in all three of its categories, medical, adult-use and international, the latter of which more than doubled its revenue in the quarter, led by strong medical sales in Germany and Poland.
Storz & Bickel, Canopy's vaporizer and device segment, slipped 4% to C$15.1 million, weighed down by softer consumer spending.